PUBLISHER: IMARC | PRODUCT CODE: 1347514
PUBLISHER: IMARC | PRODUCT CODE: 1347514
The global high-throughput screening market size reached US$ 23.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 38.3 Billion by 2028, exhibiting a growth rate (CAGR) of 8.5% during 2023-2028.
High-throughput screening (HTS) is a drug discovery process that allows automated testing of different chemical and biological compounds for a biological target. It relies on liquid handling devices, robotics, plate readers, and dedicated software for instrumentation control and data processing. It enables sample minimization, high-speed automation, and single-molecule and low background signals detection. HTS helps scientists generate and utilize large datasets for answering complex biological questions. As a result, it finds wide applications in pharmaceuticals, biotech and academic institutes, target validation, and the identification of genes that modulate a particular biological pathway.
At present, there is a rise in the utilization of HTS for minimizing the time required for manufacturing a drug. This, along with the development of new medicines for treating various life-threatening diseases, represents one of the key factors driving the market. Moreover, governments of several countries are investing in new technologies, such as a microplate-free approach, clustered regularly interspaced short palindromic repeats (CRISPR) and RNA interference (RNAi), and artificial intelligence (AI) and machine learning (ML). This, coupled with the increasing application of automation in HTS and fast data processing around the world, is propelling the growth of the market. Furthermore, key market players are introducing label-free technology to provide simple methods for studying complex biological pathways and reduce the risk of drug failure caused by toxicity. These players are also investing in research and development (R&D) activities to develop new technologies in HTS. Besides this, they are launching a time-resolved Forster resonance energy transfer (TR-FRET) version of the transcreener assay for various enzymes. These innovations are projected to bolster the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global high-throughput screening market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on technology, products and services, applications and end user.
Ultra-High-Throughput Screening
Cell-Based Assays
Lab-on-a-Chip
Label-Free Technology
Instruments
Reagents and Kits
Services
Target Identification and Validation
Primary and Secondary Screening
Toxicology Assessment
Others
Pharmaceutical and Biotechnology Firms
Academic and Government Institutes
Contract Research Organizations
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Agilent Technologies Inc., Aurora Biomed Inc., Axxam S.p.A, Beckman Coulter Inc. (Danaher Corporation), Bio-RAD Laboratories Inc., Charles River Laboratories International Inc., Corning Incorporated, Luminex Corporation (DiaSorin), Perkinelmer Inc., Sygnature Discovery, Tecan Group Ltd. and Thermo Fisher Scientific.